<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Atlanta, Georgia–(Newsfile Corp. – July 6, 2021) – Holzer & Holzer, LLC is investigating whether Provention Bio, Inc. (“Provention” or the “Company”) (NASDAQ: PRVB) complied with federal securities laws. On July 6, 2021, Provention announced the issuance of a Complete Response Letter (“CRL”) by the FDA for the Company’s Biologics License Application (“BLA”) for the drug Teplizumab. Specifically, the FDA noted that a recent study “failed to show Pharmacokinetic comparability” and notified Provention that…
...read full article on Newsfile Corp
